Global dissemination of β-lactamases mediating resistance to cephalosporins and carbapenems

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 2, 2004, Pages 317-327

  Gootz, Thomas D ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Ambler class A, B, C and D lactamases; Carbapenemase; Escherichia coli; Extended spectrum lactamases; Klebsiella pneumoniae; OXA; SHV; TEM; Third generation cephalosporins; lactamases

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFALORIDINE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; EDETIC ACID; GENTAMICIN; IMIPENEM; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PORIN; SULBACTAM; TAZOBACTAM; UNINDEXED DRUG;

ACINETOBACTER; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL CHROMOSOME; BACTEROIDES FRAGILIS; DRUG POTENCY; ENTEROBACTERIACEAE; ENZYME INHIBITION; ENZYME SUBSTRATE; ESCHERICHIA COLI; GENE IDENTIFICATION; GENETIC VARIABILITY; GRAM NEGATIVE BACTERIUM; INTEGRON; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMID; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA ENTERICA; STENOTROPHOMONAS MALTOPHILIA;

EID: 2942588985     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.2.2.317     Document Type: Review

References (82)

1. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39, 1211-1233 (1995).
2. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8, 557-584 (1995).
3. Medeiros AA. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24(Suppl. 1), S19-S45 (1997).
4. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin. Microbiol. Revs. 14, 933-951 (2001).
5. Philippon, A, Arlet, G, Jacoby, GA. Plasmid-determined ampC-type β-lactamases. Antimicrob. Agents Chemother. 46, 1-11 (2002).
6. Richmond MH, Sykes RB. The β-lactamases of Gram-negative bacteria and their possible physiological role. Adv. Microb. Physiol. 9, 31-88 (1973).
7. Ambler RP. The structure of β-lactamases. Phil. Trans. R. Soc. Lond. Biol. 289, 321-331 (1980).
8. Bush K. New β-lactamases in Gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32, 1085-1089 (2001).
9. Knox JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity and three-dimensional structure. Antimicrob. Agents Chemother. 39, 2593-2601 (1995).
10. Massova I, Mobashery S. Molecular basis for interactions between β-lactam antibitotics and β-lactamases. Acc. Chem. Res. 30,162-168 (1997).
11. Bulchev A, Massova I, Miyashita K, Mobashery S. Nuances of mechanisms and their implications for evolution of the versatile β-lactamase activity: from biosynthetic enzymes to drug resistance factors. J. Am. Chem. Soc. 119, 7619-7625 (1997).
12. Maveyraud L, Mourey L, Kotra L et al. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A β-lactamases from antibiotic-resistant bacteria. J. Am. Chem. Soc. 120, 9748-9752 (1998).
13. Taibi-Tronche P, Massova I, Vakulenko S, Lerner SA, Mobashery S. Evidence for structural elasticity of class A β-lactamases in the course of catalytic turnover of the novel cephalosporin cefepime. J. Am. Chem. Soc. 118, 7441-7448 (1996).
14. Nukaga M, Mayama K, Crichlow GV, Knox JR. Structure of an extended-spectrum class A β-lactamase from Proteus vulgaris K1. J. Mol. Biol. 317, 109-117 (2002).
15. Rasmussen BA, Bush K. Carbapenemhydrolyzing β-lactamases. Antimicrob. Agents Chemother. 41, 223-232 (1997).
16. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8, 321-331 (2002).
17. Pottumarthy S, Smith Moland E, Juretschko S, Swanzy SR, Thomson KS, Fritsche, TR. NmcA carbapenemhydrolyzing enzyme in Enterobacter cloacae in North America. Emer. Infect. Dis. 9, 999-1002 (2003).
18. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 45, 1151-1161 (2001).
19. Majiduddin FK, Palzkill T. Amino acid sequence requirements at residues 69 and 238 for the SME-1 β-lactamase to confer resistance to β-lactam antibiotics. Antimicrob. Agents Chemother. 47, 1062-1067 (2003).
20. Hernandez-Alles S, Alberti S, Alvarez D et al. Porin expression in clinical isolates of Klebsiella pneumoniae. Microbiology 145, 673-679 (1999).
21. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 47, 1297-1300 (2003).
22. TEM genes and their relationship to β-lactam resistance. Antimicrob. Agents Chemother. 46, 4035-4037 (2002).
23. Livermore DM. Acquired carbapenemases. J. Antimicrob. Chemother. 39, 673-676 (1997).
24. Hirakata Y, Yamaguchi T, Nakano M et al. Clinical and bacteriological characteristics of IMP-type metallo-β-lactamase-producing Pseudomonas aeruginosa. Clin. Infect. Dis. 37, 26-32 (2003).
25. VIM2 gene cassettes. J. Antimicrob. Chemother. 49, 837-840 (2002).
26. Yan J-J, Ko W-C, Chuang C-L, Win J-J. Metallo-β-lactamase-producing enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J. Antimicrob. Chemother. 50, 503-511 (2002).
27. VIM-2-containing integrons from Pseudomonas aeruginosa plasmids encoding the VIM-2 metallo-β -lactamase. FEMS Microbiol. Lett. 195, 145-150 (2001).
28. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr. Opin. Microbiol. 3, 489-495 (2000).
29. Beadle BM, Shoichet BK. Structural basis for imipenem inhibition of class C β-lactamases. Antimicrob. Agents Chemother. 46, 3978-3980 (2002).
30. Vakulenko SB, Golemi D, Geryk B et al. Mutational replacement of leu-293 in the class C Enterobacter cloacae P99 β-lactamase confers increased MIC of cefepime. Antimicrob. Agents Chemother. 46, 1966-1970 (2002).
31. Crichlow GV, Nukaga M, Doppalapudi VR, Buynak FD, Knox JR. Inhibition of class C β-lactamases: structure of a reaction intermediate with a cephem sulfone. Biochemistry 40, 6233-6239 (2001).
32. Hanson ND, Sanders CC. Regulation of inducible ampC β-lactamase expression among enterobacteriaceae. Curr. Pharm. Design. 5, 881-894 (1999).
33. Siu LK, Lu P-L, Chen J-Y, Lin FM, Chang S-C. High-level expression of ampC β-lactamase due to insertion of nucleotides between -10 and -35 promoter sequences in Escherichia coli clinical isolates: cases not responsive to extended-spectrum cephalosporin treatment. Antimicrob. Agents Chemother. 47, 2138-2144 (2003).
34. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48, 15-22 (2004).
35. Thomson KS, Smith Moland E. Version 2000: the new β-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect. 2, 1225-1235 (2000).
36. Afzal-Shah M, Woodford N, Livermore DM. Characterization of oxa-25, oxa-26 and oxa-27, molecular class D β-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 45, 583-588 (2001).
37. Golemi D, Maveyraud L, Vakulenko S et al. The first structural and mechanistic insights for class D β-lactamases: evidence for a novel catalytic process for turnover of β-lactam antibiotics. J. Am. Chem. Soc. 122, 6132-6133 (2000).
38. Maveyraud L, Golemi-Kotra D, Ishiwata A, Meroueh O, Mobashery S, Samama J-P. High-resolution x-ray structure of an acylenzyme species for the class D oxa-10 β-lactamase. J. Am. Chem. Soc. 124, 2461-2465 (2002).
39. Poirel L, Girlich T, Nordman P. Oxa-28, an extended-spectrum variant of oxa-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob. Agents Chemother. 45, 447-453 (2001).
40. Philippon LN, Naas T, Bouthors AT et al. Oxa- 18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41, 2188-2195 (1997).
41. Daniel F, Hall LM, Livermore DM. Laboratory mutants of oxa-10 β-lactamase giving ceftazidime resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 43, 339-344 (1999).
42. Livermore DM. Bacterial resistance: origins, epidemiology and impact. Clin. Infect. Dis. 36(Suppl. 1), S11-S23 (2003).
43. Thomson KS, Sanders CC, Smith Moland E. Use of microdilution panels with and without β-lactamase inhibitors as a phenotypic test for β-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii and Serratia marcescens. Antimicrob. Agents Chemother. 43, 1393-1400 (1999).
44. Perilli M, Sgatore B, De Massis MR et al. TEM-72, a new extended-spectrum β-lactamase detected in Proteus mirabilis and Morganella morganii in Italy. Antimicrob. Agents Chemother. 44, 2537-2539 (2000).
45. Hujer AM, Hujer KM, Helfand MS, Anderson VE, Bonomo RA. Amino acid substitutions at ambler position gly238 in the SHV-1 β -lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins. Antimicrob. Agents Chemother. 46, 3971-3977 (2002).
46. Majiduddin FK, Palzkill T. An analysis of why highly similar enzymes evolve differently. Genetics 163, 457-466 (2003).
47. Huletsky AJ, Knox JR, Levesque RC. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type β-lactamase probed by site-directed mutagenesis and three-dimensional modeling. J. Biol. Chem. 268, 3690-3697 (1993).
48. Wang Y, Minasov G, Shoichet BK. The structural bases of antibiotic resistance in the clinically derived mutant β-lactamases TEM-30, TEM-32 and TEM-34. J. Biol. Chem. 277, 32149-32156 (2002).
49. National Committee for Clinical Laboratory Standards, Performance standards for susceptibility testing; 14th Informational Supplement M100-S14, 24, 1. National Committee for Clinical Laboratory Standards, PA, USA (2004).
50. Thomson KS. Controversies about ESBL and AmpC β-lactamases. Emerg. Infect. Dis. 7(2), 333-336 (2001).
51. Aumeran C, Chanal C, Labia R, Sirot D, Sirot J, Bonnet R. Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum β-lactamase CTX-M-9. Antimicrob. Agents Chemother. 47, 2958-2961 (2003).
52. Winokur PL, Canton R, Casellas J-M, Legakis N. Variations in prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas and the Western Pacific region. Clin. Infect. Dis. 32(Suppl. 2), S94-S103 (2001).
53. Goossens H, MYSTIC study group Europe. MYSTIC program: summary of European data from 1997 to 2000. Diag. Microbiol. Infect. Dis. 41, 183-189 (2001).
54. Mathai D, Todd Lewis M, Kugler KC, Pfaller MA, Jones RN. Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I-results from the SENTRY antimicrobial surveillance program (North America, 1998). Diag. Microbiol. Infect. Dis. 39, 105-116 (2001).
55. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN. Prevalence of extended-spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY antimicrobial surveillance program (1998-1999). Diag. Microbiol. Infect. Dis. 42, 193-198 (2002).
56. Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diag. Microbiol. Infect. Dis. 44, 273-280 (2003).
57. Neuhauser, MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units. JAMA 289, 885-888 (2003).
58. Smith Moland E, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson K. Occurrence of newer β-lactamases in Klebsiella pneumoniae isolates from 24 US hospitals. Antimicrob. Agents Chemother. 46, 3837-3842 (2002).
59. Quale JM, Landman D, Bradford PA et al. Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin. Infect. Dis. 35, 834-841 (2002).
60. Nathisuwan S, Burgess D, Lewis JS 2nd. Extended-spectrum β-lactamases: epidemiology, detection and treatment. Pharmacotherapy 21, 920-928 (2001).
61. Tenover FC, Mohanned MJ, Gorton TS, Dembek ZF. Detection and reporting of organisms producing extended-spectrum β-lactamase: survey of laboratories in Connecticut. J. Clin. Microbiol. 37, 4065-4070 (1999).
62. Tenover FC, Raney PM, Williams PP et al. Evaluation of the NCCLS extended-spectrum β-lactamase confirmation methods for Escherichia coli with isolates collected during project ICARE. J. Clin. Microbiol. 41, 3142-3146 (2003).
63. Rasheed JK, Anderson GJ, Yigit H et al. Characterization of the extended-spectrum β-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob. Agents Chemother. 44, 2382-2388 (2000).
64. Jacoby GA, Sutton L. Properties of plasmids responsible for production of extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35, 164-169 (1991).
65. Burgess DS, Hall RG 2nd, Lewis JS 2nd, Jorgensen JH, Patterson JE. Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing- isolates over a 2-year period. Pharmacotherapy 23, 1232-1237 (2003).
66. Rodriguez-Bano J, Navarro D, Martinez-Martinez L et al. Clinical epidemiology of extended-spectrum β-lactamase producing enterobacteriaceae in the community. 42nd Interscience Conf Antimicrobial Agents Chemother (2002) (Abstract C2-1880).
67. Doi Y, Shibata N, Shibayama K et al. Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate. Antimicrob. Agents Chemother. 46, 2427-2434 (2002).
68. Queenan A-M, Jenkins S, Bush K. Cloning and biochemical characterization of FOX-5, an ampC-type plasmid-encoded β-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob. Agents Chemother. 45, 3189-3194 (2001).
69. Rottman M, Benzerara Y, Hanau-Bercot B, Bizet C, Philippon A, Arlet G. Chromosomal ampC genes in Enterobacter species other than Enterobacter cloacae and ancestral association of the ACT-1 plasmid-encoded cephalosporinase to Enterobacter asburiae. FEMS Microbiol. Lett. 210, 87-92 (2002).
70. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated ampC β-lactamase and the loss of an outer membrane porin. Antimicrob. Agents Chemother. 41, 563-569 (1997).
71. Reisbig MD, Hossain A, Hanson N. Factors influencing gene expression and resistance for Gram-negative organisms expressing plasmid-encoded ampC genes of Enterobacter origin. J. Antimicrob. Chemother. 51, 1141-1151 (2003).
72. Fortineau N, Poirel L, Nordmann P. Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae. J. Antimicrob. Chemother. 47, 207-210 (2001).
73. Recchia GD, Sherratt DJ. 'Gene acquisition in bacteria by integron-mediated site-specific recombination'. In: Mobile DNA II. Craig NL, Craigie R, Gellert M and Lanbowitz AM (Eds), ASM Press, DC, USA 162-173 (2002).
74. Martinez-Martinez L, Pascual A. Hernandez-Alles S et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. 43, 1669-1673 (1999).
75. Yigit H, Anderson GJ, Biddle JW et al. Carbapenem resistance in a clinical isolate of Enterobacter aerogenes is associated with decreased expression of ompF and ompC porin analogs. Antimicrob. Agents Chemother. 46, 3817-3822 (2002).
76. Coudron PE, Hanson ND, Climo MW. Occurrence of extended-spectrum and ampC β-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 ampC β-lactamases. J. Clin. Microbiol, 41, 772-777 (2003).
77. Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of plasmid-mediated ampC β-lactamases in the United States. Antimicrob. Agents Chemother. 47, (2004) (In Press).
78. Odeh R, Kelkar S, Hujer AM, Bonomo RA, Schreckenberger PC, Quinn JP. Broad resistance due to plasmid-mediated ampC β -lactamases in clinical isolates of Escherichia coli. Clin. Infect. Dis. 35, 140-145 (2002).
79. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect. Control Hosp. Epidemiol. 21, 455-458 (2000).
80. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32, 1162-1171 (2001).
81. Rahal JJ, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 280, 1233-1237 (1998).
82. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 21, 583-592 (2001).